Method of treating diabetic peripheral neuropathy through amendment of pre-neuronal diabetic coagulative micro-angiopathy and neuronal deficiency of mitochondrial ATP production, and through induction of neuronal regeneration

Abstract

DPN is an intractable and tormenting neurovascular and dermal disorder. Two patients of DPN of stocking-glove pattern were treated with SAG for treatment of microvascuar coagulopathy, induction of vasodilation and possible induction of angioneogenesis; with ALC for ATP generation through mitochondrial beta-oxidation of fats; and with ALA for antioxidative stress to prevent precipitation of vascular damage and to prevent DPN recurrence. SAG+ALC was to cure maceration. Thus, SAG+ALC+ALA was effective in mitigating and curing their distresses. It shall be one of the logical and practical means of prompt DPN therapy not only to alleviate DPN but also to lead to “cure.”

1 . A method of treating diabetic neuropathy, including a first stage of treatment with sarpogrelate (SAG) for a period of time, a second stage of treatment with SAG and acetyl-L-carnitine (ALC) for a period of time; and a third stage of treatment with ALC and epalrestat (EPR) for a period of time. 
     
     
         2 . The method as  claim 1 , in which in the first stage, the dosage of SAG is 600 mg per day. 
     
     
         3 . A method as  claim 1 , in which, in the second stage of treatment with ALC, the ALC dosage was 1500 mg per day. 
     
     
         4 . A method as  claim 1 , in which, in the third stage of treatment with EPR, the dosage was 300 mg per day. 
     
     
         5 . A method as  claim 1 , in which in the fourth stage of treatment with ALA, the dosage was 600 mg per day. 
     
     
         6 . A photographic evidence as  claim 1 , in which the changing treatment of DPN with SAG+ALC in a case of hyperinsulinemic pre-diabetic DPN. 
     
     
         7 . A photographic evidence as  claim 1 , in which the charging treatment of DPN with ALC and SAG was shown to promptly heal dermatological abnormalities of skin discoloration and maceration in the depth along with rescuing neurological distresses. 
     
     
         8 . A method as  claim 1 , in which any combinations of SAG with the metabolic modifiers as ALC, or EPR, especially the SAG-ALC appeared promising in the treatment of DPN with eventual attainment of neuronal regeneration. 
     
     
         9 . A method as  claim 1 , in which the contribution of SAG+ALC+ALA halted the DPN, and seemed to have cured it for the 5 years of follow-up without signs and symptoms of recurrence: eventual attainment of neuronal regeneration with this SAG+ALCX+ALA principle. 
     
     
         10 . This SAG+ALC+ALA principle may be applicable to prevention of untoward development of DPN candidates as cases of hyperinsulinemic insulin resistance, those of pre-diabetic chronic post-prandial hyperinsulinemia, those of ASO, and dementias of AD and others. 
     
     
         11 . The method as  claim 1 , in which in the first stage, the dosage of SAG is 300 mg per day.